Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial

Fernando Torres, Harrison Farber, Arsen Ristic, Vallerie McLaughlin, John Adams, Jinkun Zhang, Preston Klassen, William Shanahan, John Grundy, Ines Hoffmann, Christopher Cabell, Pilar Escribano Subías, Namita Sood, Anne Keogh, Gwyn D'Souza, Lewis Rubin

Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019
Journal Issue: October
Disease area: Pulmonary vascular diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Fernando Torres, Harrison Farber, Arsen Ristic, Vallerie McLaughlin, John Adams, Jinkun Zhang, Preston Klassen, William Shanahan, John Grundy, Ines Hoffmann, Christopher Cabell, Pilar Escribano Subías, Namita Sood, Anne Keogh, Gwyn D'Souza, Lewis Rubin. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: